TOLLIP inhibits lipid accumulation and the integrated stress response in alveolar macrophages to control Mycobacterium tuberculosis infection-Reference-Cited by-同舟云学术

TOLLIP inhibits lipid accumulation and the integrated stress response in alveolar macrophages to control Mycobacterium tuberculosis infection

Published:2024-03-25 Issue:4 Volume:9 Page:949-963
ISSN:2058-5276
Container-title:Nature Microbiology
language:en
Short-container-title:Nat Microbiol

Author:

Venkatasubramanian Sambasivan,Plumlee Courtney R.,Dill-McFarland Kimberly A.,Cohen Sara B.,Gern Benjamin H.^ORCID,Rane Divya A.,Meyer Mackenzie K.^ORCID,Saha Aparajita,Hinderstein Sarah A.,Pearson Gemma L.,Lietzke Anne C.,Pacheco Amanda,Chow Yu-Hua,Hung Chi F.,Soleimanpour Scott A.^ORCID,Altman Matthew,Urdahl Kevin B.,Shah Javeed A.^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

American Diabetes Association

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases

U.S. Department of Veterans Affairs

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41564-024-01641-w.pdf

Reference71 articles.

1. Shah, J. A. et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J. Immunol. 189, 1737–1746 (2012).

2. Shah, J. A. et al. A functional TOLLIP variant is associated with BCG-specific immune responses and tuberculosis. Am. J. Respir. Crit. Care Med. 196, 502–511 (2017).

3. Shah, J. A. et al. Genetic variation in toll-interacting protein is associated with leprosy susceptibility and cutaneous expression of interleukin 1 receptor antagonist. J. Infect. Dis. 213, 1189–1197 (2016).

4. Uhlén, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).

5. Jongsma, M. L. et al. An ER-associated pathway defines endosomal architecture for controlled cargo transport. Cell 166, 152–166 (2016).